Epigenetics Diagnostics Market Report 2026

Epigenetics Diagnostics Market Overview

• Epigenetics Diagnostics market size has reached to $16.56 billion in 2025 • Expected to grow to $35.17 billion in 2030 at a compound annual growth rate (CAGR) of 16.2% • Growth Driver: Growing Demand For Personalized Medicine Fueling The Growth Of The Market Due To Advancements In Genetic And Molecular Profiling • Market Trend: Innovative Clinical-Grade Epigenetic Analysis Driving Advancements In Disease Detection And Health Profiling • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Epigenetics Diagnostics Market?

Epigenetic diagnostics refers to the scientific process of detecting and analyzing modifications in gene activity, such as DNA methylation or histone changes, that occur without altering the actual DNA sequence but can significantly influence biological functions. It focuses on identifying these molecular changes to understand how they regulate gene expression and contribute to biological variability. The main products of epigenetics diagnostics include kits and reagents, software and services, and instruments. Kits and reagents are specialized research instruments for studying and analyzing epigenetic changes such as DNA methylation, histone modifications, and chromatin interactions. It includes technologies such as deoxyribonucleic acid (DNA) methylation, histone methylation, histone acetylation, large noncoding ribonucleic acid (RNA), micro ribonucleic acid (RNA) modification, and chromatin structures and is used for applications including oncology, metabolic diseases, developmental biology, immunology, cardiovascular diseases, and others. Key end users include pharmaceutical and biotechnology firms, academic and research institutes, and clinical diagnostic laboratories.

What Is The Epigenetics Diagnostics Market Growth Forecast?

The epigenetics diagnostics market size is expected to see rapid growth in the next few years. It will grow to $35.17 billion in 2030 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to technological advancements in sequencing and epigenetic analysis, rising investment in personalized medicine, expansion of oncology and metabolic disease diagnostics, integration of cloud-based bioinformatics services, increasing demand from pharmaceutical and biotechnology firms. Major trends in the forecast period include increasing adoption of epigenetic biomarker kits, rising use of next-generation sequencing and microarray systems, expansion of data analysis and bioinformatics services, growing focus on oncology and personalized medicine applications, integration of automated liquid handling and high-throughput platforms.

Global Epigenetics Diagnostics Market Segmentation

1) By Product: Kits And Reagents, Software And Services, Instruments 2) By Technology: Deoxyribonucleic Acid (DNA) Methylation, Histone Methylation, Histone Acetylation, Large NonCoding, Ribonucleic Acid (RNA), Micro Ribonucleic Acid (RNA) Modification, Chromatin Structures 3) By Application: Oncology, Metabolic Diseases, Developmental Biology, Immunology, Cardiovascular Diseases, Other Applications 4) By End User: Pharmaceutical And Biotechnology firms, Academic And Research Institutes, Clinical Diagnostic Laboratories Subsegments: 1) By Kits and Reagents: Deoxyribonucleic Acid Methylation Kits, Histone Modification Kits, Chromatin Accessibility Kits, Bisulfite Conversion Kits, Polymerase Chain Reaction Reagents, Antibodies and Probes, Enzymes and Buffers 2) By Software and Services: Data Analysis Software, Bioinformatics Services, Epigenetic Data Interpretation, Cloud-based Data Storage, Custom Assay Development, Validation and Consulting Services 3) By Instruments: Next-Generation Sequencers, Microarray Systems, Polymerase Chain Reaction and Quantitative Polymerase Chain Reaction Instruments, Mass Spectrometry Systems, Imaging Systems, Automation and Liquid Handling Systems

What Is The Driver Of The Epigenetics Diagnostics Market?

The growing demand for personalized medicine is expected to propel the growth of the epigenetics diagnostics market going forward. Personalized medicine is an approach that customizes medical treatment based on an individual’s genetic makeup, biology, and lifestyle factors. Growing demand for personalized medicine is rising due to advancements in genetic and molecular profiling, which enable treatments tailored to an individual’s unique biological makeup, improving effectiveness and reducing side effects. Epigenetics diagnostics supports personalized medicine by identifying individual epigenetic patterns that guide customized prevention and treatment plans for optimal patient outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Therefore, the growing demand for personalized medicine is driving the growth of the epigenetics diagnostics industry.

Key Players In The Global Epigenetics Diagnostics Market

Major companies operating in the epigenetics diagnostics market are F. Hoffmann-La Roche Ltd., Merck KGaA, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., GeneTex Inc., Bio-Techne Corporation, Promega Corporation, New England Biolabs Incorporated, Pacific Biosciences of California Inc., Enzo Biochem Inc., Diagenode Société Anonyme, Zymo Research Corporation, Active Motif Inc., ADmit Therapeutics SL, Epigentek Group Inc., INHERENT Biosciences Inc.

Global Epigenetics Diagnostics Market Trends and Insights

Major companies operating in the epigenetics diagnostics market are focusing on developing innovative approaches, such as clinical-grade epigenetic analysis, to enhance the accuracy, sensitivity, and clinical utility of detecting disease-associated epigenetic modifications. Clinical-grade epigenetic analysis refers to the use of validated and standardized methods to detect epigenetic changes with the accuracy and reliability required for clinical diagnosis and treatment decisions. For instance, in October 2024, EpiMedTech, a Singapore-based biotechnology company, introduced epiGeneComplete, a clinical-grade test that integrates genetic and epigenetic analysis through next-generation sequencing and advanced DNA methylation techniques to provide detailed insights into key health indicators, including aging, stress, inflammation, addiction risk, and metabolism. Conducted in CAP-accredited laboratories, this non-invasive saliva-based test offers high sensitivity and accuracy, supports personalized health profiling, and is designed as an open, adaptable platform for future diagnostic expansion, marking a notable advancement in routine health screening and early disease detection.

What Are Latest Mergers And Acquisitions In The Epigenetics Diagnostics Market?

In January 2023, Agilent Technologies Inc., a US-based biotechnology company, acquired Avida Biomed for an undisclosed amount. With this acquisition, Agilent aims to strengthen its product portfolio by enabling more advanced next-generation sequencing tools for clinical research and diagnostics, especially to accelerate research in precision oncology and cancer treatment. Avida Biomed is a US-based life sciences company that offers epigenetics diagnostics, specifically focusing on DNA methylation analysis for liquid biopsies.

Regional Outlook

North America was the largest region in the epigenetics diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Epigenetics Diagnostics Market?

The epigenetic diagnostics market consists of revenues earned by entities by providing services such as histone modification analysis, biomarker discovery, disease risk assessment, single-cell epigenetic analysis, longitudinal epigenetic monitoring, and DNA methylation profiling. The market value includes the value of related goods sold by the service provider or included within the service offering. The epigenetic diagnostics market also includes sales of instruments, sample preparation tools, workflow control kits, and liquid biopsy assays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.